Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00771329 · ClinicalTrials.gov registry record · Phase 1
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00771329: Completed Phase 1 study, sponsored by Biogen.
NCT00771329 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 53 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00771329, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
Phase I study designed to determine the safety and tolerability of a single dose of BIIB023 administered intravenously versus placebo to subjects with RA.
Interventions
- DRUG BIIB023
- OTHER Placebo (sterile normal saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
What the finished NCT00771329 record still lists
NCT00771329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 2 interventions - of which BIIB023 is the first listed.
NCT00771329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00771329 about?
NCT00771329 is a clinical study titled "BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis". Phase I study designed to determine the safety and tolerability of a single dose of BIIB023 administered intravenously versus placebo to subjects with RA.
What is the current status of trial NCT00771329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2008-10. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00771329?
The interventions under investigation include: BIIB023 (DRUG), Placebo (sterile normal saline) (OTHER).
Who is sponsoring clinical trial NCT00771329?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00771329's enrollment target sits among peer trials
53 948th of 2000 higher than 1,045 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia